LuciLazer — Lazertinib 80 mg, 60 pcs, Lucius

LuciLazer — Lazertinib Tablets 80 mg, 60 Tablets

Product code: 506

49170₴ 53595₴ -8% On order · from 10 days

Analogues

Lazerib LuciLazer
1
Active ingredient
Dosage form Tablets
Tablets per pack 60

LuciLazer is an advanced targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is lazertinib at a strength of 80 mg supplied as film-coated oral tablets (Lazertinib Tablets 80 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Lazertinib is an oral, highly selective, irreversible mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective against both sensitizing EGFR mutations (such as exon 19 deletions or L858R substitution) and the resistance mutation T790M. Furthermore, lazertinib exhibits high penetration across the blood-brain barrier, providing superior control of brain metastases.

Supplied in a package containing 60 tablets of 80 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciLazer 80 mg:

  • ✅ Third-Generation EGFR Inhibitor: High selectivity for sensitizing and T790M resistance mutations.
  • ✅ CNS Metastases Activity: Excellent blood-brain barrier penetration for intracranial lesion control.
  • ✅ Proven Clinical Efficacy: High objective response rates and durable disease control.
  • ✅ Convenient Oral Dosing: Taken orally once daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Leclaza).

LuciLazer is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Lazertinib (as lazertinib mesylate) — 80 mg.
  • Excipients: Microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, macrogol, colorants.

Packaging and Presentation: Film-coated tablets, 80 mg strength. Each package contains 60 tablets along with prescribing information. Labeled with LuciLazer (Lazertinib Tablets 80 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Lazertinib is a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It potently inhibits the activity of both sensitizing EGFR mutations (Ex19del, L858R) and the T790M resistance mutation while exhibiting lower potency against wild-type EGFR, which reduces the incidence of adverse skin and gastrointestinal toxicities commonly observed with first-generation TKIs.

Pharmacokinetics:

  • Absorption: Following oral administration, lazertinib is absorbed moderately fast; peak plasma concentration (Tmax) is achieved within approximately 2 to 4 hours. Food intake has no clinically significant effect on absorption.
  • Distribution: Moderate human plasma protein binding. The drug effectively penetrates central nervous system tissues.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (specifically CYP3A4 and CYP2C9).
  • Elimination: Excreted predominantly via feces and renally as metabolites. Terminal elimination half-life (T1/2) averages approximately 24 to 30 hours.

LuciLazer is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations or the T790M resistance mutation who have previously received EGFR tyrosine kinase inhibitor therapy, as well as for first-line treatment.

LuciLazer is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard dose is 240 mg (three 80 mg tablets) once daily.

Administration Guidelines:
Tablets should be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses to make up for a missed dose).

Administration of LuciLazer is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to lazertinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.

Lazertinib is metabolized by cytochrome P450 enzymes (predominantly CYP3A4 and CYP2C9):

  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease lazertinib plasma concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • Strong CYP3A4 Inhibitors: May increase systemic lazertinib exposure and toxicity risks (use with caution).
  • Transporter Substrates: Lazertinib may affect certain protein transport systems.

Pregnancy:
LuciLazer is contraindicated during pregnancy. Based on its mechanism of action, lazertinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 6 weeks following the final dose.

Lactation:
Excretion of lazertinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions (Very Common): Paronychia (nail fold inflammation), rash, dry dermatitis, pruritus.
  • Gastrointestinal Tract: Diarrhea, stomatitis, nausea, decreased appetite, constipation.
  • General Disorders: Fatigue, asthenia, paresthesia, peripheral edema.
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), increased blood creatine phosphokinase (CPK), leukopenia, thrombocytopenia.
  • Serious Effects: Interstitial lung disease (pneumonitis), QT interval prolongation.

Symptoms:
Specific acute overdose symptoms of lazertinib are unestablished. Anticipated manifestations include exacerbated dermatologic reactions, diarrhea, fatigue, and laboratory abnormalities.

Treatment:
No specific antidote exists. In case of overdose, discontinue treatment and initiate supportive and symptomatic care under vital organ monitoring.

Storage Requirements for LuciLazer 80 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciLazer 80 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Lazertinib Tablets 80 mg, and 60 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00